Sign In
Buy CAI
$15.67
-0.420 (-2.61%)
At Close: Jul 31, 2026
Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection
05:29am, Tuesday, 21'st Jul 2026
Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implying ~35% upside, and 23%-26% 2026 estimated revenue growth. CAI's proprietary WES/WTS/WGS technology a
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
08:30am, Thursday, 16'th Jul 2026
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
08:30am, Tuesday, 14'th Jul 2026
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will o
Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
08:30am, Wednesday, 01'st Jul 2026
Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologies IRVING, Texas, July 1, 2026
Virginia Information Technologies Agency Selects CAI to Deliver Statewide Cybersecurity Services to Local Governments
09:07am, Wednesday, 24'th Jun 2026
ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewide contract with the Virginia Information Technologies Agency (VITA) to provide Security Operations
CAI Named to Newsweek's America's Greatest Workplaces in Tech 2026
09:06am, Wednesday, 17'th Jun 2026
ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it has been named to Newsweek's America's Greatest Workplaces in Tech 2026 list.
Caris Life Sciences Announces Dual Listing on NYSE Texas
08:30am, Tuesday, 16'th Jun 2026
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual
Caris Life Sciences: The Discount To Peers Looks Hard To Ignore
07:57am, Friday, 12'th Jun 2026
Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and positive free cash flow. CAI's genomic database of over one million cases underpins future products li
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:48pm, Monday, 08'th Jun 2026
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Caris Life Sciences Announces Share Repurchase Program
08:30am, Monday, 08'th Jun 2026
IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced
Capitan Investment Ltd. Announces Adoption of Semi-Annual Reporting
02:11pm, Thursday, 28'th May 2026
Calgary, Alberta--(Newsfile Corp. - May 28, 2026) - Capitan Investment Ltd. (TSXV: CAI) (the "Corporation") announces that it has elected to adopt semi-annual financial reporting in reliance on the Co
Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma I
CAI Advances Multicloud and Secure AI Strategy with AWS and Microsoft
09:02am, Wednesday, 20'th May 2026
ALLENTOWN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, with more than 40 years of expertise delivering technology solutions to public sector and commercial organizations, announ
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences®
